Exelixis, Inc.
EXEL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000939767
In the last 90 days, Exelixis, Inc. insiders filed 0 open-market purchases and 1 sale; 760 institutions reported holding it in 13F filings for Q2 2026, worth $14.1B in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Exelixis, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 380
- +16 vs. Q1 2023
- Shares held
- 273.2M
- −7.28M (−2.6%) vs. Q1 2023
- Total value
- $5.22B
- −$224.5M (−4.1%) vs. Q1 2023
- New holders
- 49
- 108 more added
- Sold out
- 33
- 154 more reduced
2 institutions that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EXEL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 760 | $14.1B |
| Q1 2026 | 701 | $11.1B |
| Q4 2025 | 685 | $11.4B |
| Q3 2025 | 622 | $10.4B |
| Q2 2025 | 635 | $11.2B |
| Q1 2025 | 559 | $9.35B |
| Q4 2024 | 519 | $8.33B |
| Q3 2024 | 454 | $6.45B |
| Q2 2024 | 416 | $5.47B |
| Q1 2024 | 422 | $6.02B |
| Q4 2023 | 427 | $6.21B |
| Q3 2023 | 400 | $5.78B |
| Q2 2023 | 380 | $5.22B |
| Q1 2023 | 366 | $5.45B |
| Q4 2022 | 388 | $4.49B |
| Q3 2022 | 402 | $4.33B |
| Q2 2022 | 376 | $5.78B |
| Q1 2022 | 363 | $6.11B |
| Q4 2021 | 329 | $4.89B |
| Q3 2021 | 341 | $5.63B |
| Q2 2021 | 345 | $4.88B |
| Q1 2021 | 348 | $5.92B |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Exelixis, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Simplex Trading, LLC | 0 | $0 | 0.00% | −7,792−100.0% | Sold out |
| DuPont Capital Management Corp | 0 | $0 | 0.00% | −7,525−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −2,009−100.0% | Sold out |
| Belpointe Asset Management LLC | 0 | $0 | 0.00% | −1,892−100.0% | Sold out |
| Baillie Gifford & Co | 0 | $0 | 0.00% | −1,395−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −735−100.0% | Sold out |
| WealthPLAN Partners, LLC | 0 | $0 | 0.00% | −525−100.0% | Sold out |
| Asset Management One Co.,Ltd. | 0 | $0 | 0.00% | −249−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −195−100.0% | Sold out |
| Schubert & Co | 0 | $0 | 0.00% | −111−100.0% | Sold out |
| Coston, McIsaac & Partners | 0 | $0 | 0.00% | −130−100.0% | Sold out |
| Steward Financial Group LLC | 0 | $0 | 0.00% | −74−100.0% | Sold out |
| Ameritas Advisory Services, LLC | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Kula Investments, LLC | – | – | – | – | Not filed |
| Ahrens Investment Partners LLC | – | – | – | – | Not filed |